Introduction
============

Identifying the genetic basis of complex phenotypes is a central goal of modern biology because 1) many fundamental aspects of evolution, such as pleiotropy ([@evy229-B92]), result from the genotype--phenotype relationship ([@evy229-B85]; [@evy229-B30]); 2) our ability to ultimately predict evolution depends on understanding these evolutionary dynamics; and 3) characterizing the genetic basis of complex traits, particularly disease-related traits such as cancer risk ([@evy229-B3]; [@evy229-B81]), is of critical importance for conservation and medicine ([@evy229-B31]; [@evy229-B14]; [@evy229-B2]; [@evy229-B5]; [@evy229-B53]). Indeed, understanding the genotype--phenotype relationship is crucial for both assessing disease risk and developing personalized prevention and treatment ([@evy229-B40]; [@evy229-B95]; [@evy229-B8]; [@evy229-B24]). Genomic advances have enabled the identification of loci associated with oncogenesis, tumor progression, and even cancer regression and spontaneous remission ([@evy229-B75]; [@evy229-B98]; [@evy229-B25]; [@evy229-B89]; [@evy229-B43]). Comparative oncology should provide insight into the genetic basis of cancer risk, tumor development, and the pathogenicity of human cancers, particularly due to our limited ability to monitor natural, untreated tumor progression in human patients for obvious ethical considerations ([@evy229-B41]; [@evy229-B82]; Millanta et al. [@evy229-B63]).

Most cancers are somatic in origin, but a few transmissible cancers have been documented (reviewed in [@evy229-B72]). Such cancers are rare, with the only natural cases found in dogs (canine transmissible venereal tumor or CTVT; [@evy229-B70]), bivalves ([@evy229-B62]), and the Tasmanian devil (devil facial tumor disease or DFTD; [@evy229-B74]; [@evy229-B77]). Yet within these species, six transmissible cancers have recently been discovered (i.e., several in bivalves and a second in Tasmanian devils; [@evy229-B62]; [@evy229-B77]), suggesting that these types of cancers may be more common than previously thought. Unlike dogs and bivalves, the Tasmanian devil (*Sarcophilus harrisii*) is threatened with extinction by the emergence of two clonally transmissible cancers ([@evy229-B33]; [@evy229-B68]; [@evy229-B77]; [@evy229-B86]; [@evy229-B88]). Devil facial tumor disease 1 and 2 (DFT1 and DFT2, respectively) are contagious tumor cell lines and spread via biting, which is common during social interactions ([@evy229-B28]). DFT1 was first discovered in northeastern Tasmania in 1996 and has since spread more than 80% of the way across the island, causing significant population declines ([@evy229-B58]; [@evy229-B59]). DFT2 was discovered in 2014 and is currently restricted to a small region of southeastern Tasmania ([@evy229-B77]). Although comparatively little is known about DFT2 relative to DFT1, the tumors are histologically, cytogenetically, and genetically distinct despite gross morphological similarities and are of independent origin ([@evy229-B77]; [@evy229-B86]).

Low devil genetic diversity ([@evy229-B64]; [@evy229-B34]) and silencing of cell surface MHC molecules by DFTD have putatively led to universal susceptibility and ∼100% mortality ([@evy229-B84]). Yet all devil populations continue to persist, suggesting that devils are responding to DFTD ([@evy229-B36]; [@evy229-B45]). Recent work in devils has found evidence of an immune response to DFT1 ([@evy229-B77]), rapid evolution in genes related to immune function and cancer risk following disease arrival ([@evy229-B19]), and few loci of large-effect underlying disease-related phenotypes such as survival following infection ([@evy229-B53]). Collectively, these studies suggest the evolution of resistance and/or tolerance to DFT1 in devils.

Recently, natural (i.e., unmedicated) tumor regression has been detected in northwestern Tasmania ([fig. 1](#evy229-F1){ref-type="fig"}; [@evy229-B77]; [@evy229-B96]). In these cases, devils with previously confirmed DFT1 were recaptured with either substantial tumor shrinkage or entire disappearance of the tumor. Recent work on CTVT regression (which, unlike in DFT1, is common) has shown that host response plays a critical role in triggering tumor regression ([@evy229-B21]), suggesting that DFT1 regression may also be driven by the devil immune system. [@evy229-B96] recently used whole-genome sequencing (WGS) and a genome-wide association (GWA) approach to compare the genomes of six devils with regressed tumors to the genomes of five devils with nonregressed tumors. Despite significant statistical limitations due to unavoidable sample size limitations (i.e., regression is a rare, novel phenotype), [@evy229-B96] found evidence that loci involved with angiogenesis may be associated with tumor regression. Although GWA methods are a classical approach for identifying the genomic basis of variation in disease phenotypes, these studies often require several thousand samples to attain appropriate statistical power ([@evy229-B97]). Even for species such as *S. harrisii* with small populations and strong linkage disequilibrium ([@evy229-B19]), many more than a dozen samples are needed to reliably detect variants of an appreciable effect in a case--control GWA framework ([@evy229-B39]; [@evy229-B53]). Furthermore, [@evy229-B21] showed that tumor regression in CTVT is polygenic and driven by several genes, most notably cyto/chemokines involved with inflammation and interferon signaling. [@evy229-B96], however, looked at significant associations for individual SNPs and indels. Although methods for incorporating gene set analyses and other polygenic approaches into a GWA framework exist ([@evy229-B66]), these models also require many more than a dozen samples ([@evy229-B6]), thus precluding their use for investigating the genetic basis of tumor regression in Tasmanian devils.

![---Sampling of *Sarcophilus harrisii*. We collected tissue samples from seven individuals that underwent tumor regression and three individuals that did not for whole-genome sequencing. Sampling region as well as the sites of discovery (i.e., putative sites of origin) for DFT1 and DFT2 are indicated in the inset.](evy229f1){#evy229-F1}

We therefore used WGS and *F*~ST~-based approaches to compare the genomes of seven individuals that underwent tumor regression (i.e., cases) with those of three infected individuals that did not (i.e., controls) to identify the genetic/polygenic basis of natural tumor regression in Tasmanian devils. We approximately doubled the genome coverage of [@evy229-B96]; 10--15× to 20--30×) and genotyped SNPs, indels, and larger structural variants (SVs) for each individual; the latter were not previously investigated. Genomic instability has repeatedly been shown to be important in many human cancers (e.g., [@evy229-B32]; [@evy229-B1]) as well as in DFT1 and DFT2 ([@evy229-B15]; [@evy229-B68]; [@evy229-B77]; [@evy229-B86]). SVs in the human genome, however, can also be associated with disease susceptibility ([@evy229-B90]; [@evy229-B52]) and may have a higher probability, relative to SNPs, of affecting phenotypes ([@evy229-B11]). We used these three classes of genetic variation to characterize the polygenic basis of tumor regression by identifying large candidate genomic regions and particular biological pathways that differentiated cases and controls. Previous work suggested that loci involved with angiogenesis ([@evy229-B96]), chemokine signaling ([@evy229-B21]), and cell adhesion ([@evy229-B19]; [@evy229-B53]) may be important to tumor regression/devil response to DFT1. [@evy229-B21] also showed that the differential expression of key genes leads to CTVT regression, and the predominance of expression differentiation underlying rapid, adaptive responses has been documented in humans ([@evy229-B22]) and other systems ([@evy229-B42]; [@evy229-B54]). We therefore predicted that loci involved with one or more of these pathways would be highly differentiated between cases and controls, and that this differentiation would be biased toward putative regulatory rather than protein-coding regions. Although transcriptomics is most often used to identify differential gene expression and regulatory variation ([@evy229-B67]; [@evy229-B4]; [@evy229-B78]), serial sampling of devil tissue pre and postregression was not feasible due to the stochasticity of recapture events. We therefore identified significantly conserved noncoding sequences across devils and other mammals as putative regulatory elements. We then mapped highly differentiated variants to these regions to identify putative regulatory variation underlying the regression phenotype.

Materials and Methods
=====================

Sampling and WGS
----------------

We sequenced the genomes of ten *S. harrisii* from northwestern Tasmania ([fig. 1](#evy229-F1){ref-type="fig"}). All devils were confirmed to have DFT1. Seven of these individuals (six females, one male) exhibited tumor regression (i.e., cases), and three individuals (one female, two males) did not (i.e., controls). Individuals were classified as possessing the regression phenotype if tumor volume decreased ≥15% of the initial tumor volume upon recapture. Genomic DNA was extracted from ear biopsies. Whole-genomes for each individual were sequenced 150 bp paired-end on an Illumina HiSeq X platform to ∼30× coverage. Sequencing was performed at the Northwest Genomics Center at the University of Washington (Seattle, Washington, USA) and GENEWIZ (South Plainfield, New Jersey, USA). All raw data were deposited in the Sequence Read Archive (SRA) under BioProject PRJNA450403 and accessions SRR7015138, SRR7015139, SRR7015141--SRR7015147, and SRR7015149.

Alignments and Variant Calling
------------------------------

We merged raw reads with FLASH2 ([@evy229-B46]) and trimmed with Sickle ([@evy229-B37]). We then aligned merged and unmerged reads to the reference genome (downloaded from Ensembl January 2016; [@evy229-B68]) using the BWA-MEM algorithm ([@evy229-B46]). We identified SNPs and indels using HaplotypeCaller in GATK ([@evy229-B60]; [@evy229-B16]) as previously described ([@evy229-B54]). We identified 2,822,764 and 1,194,776 raw SNPs and indels, respectively. Raw variants were filtered in VCFtools ([@evy229-B13]) and were required to possess a minimum depth value of 15 as well as a minimum genotype quality of 60. Following filtering, the final SNP and indel data sets contained 1, 271, 835 and 281, 046 variants, respectively.

Identifying the Genomic Basis of Tumor Regression
-------------------------------------------------

We used the Genotype Phenotype Association Toolkit (GPAT++) from the vcflib package ([@evy229-B26]) as previously described ([@evy229-B17]) to identify case--control genomic differentiation. To avoid the high false positive rate inherent to any *F*~ST~-based outlier detection approach using small sample sizes ([@evy229-B47]; [@evy229-B91]), we used the segmentFst function from GPAT++ to identify candidate genomic regions with continuous, elevated *F*~ST~ values relative to the surrounding genome ([@evy229-B17]); we were much less likely to find highly differentiated, large genomic regions encompassing many variants through sampling error than single variants spread across the genome. We used this approach to identify candidate genomic regions using the SNP and indel data independently. Differentiation was visualized as a Manhattan plot using the pFst function from GPAT++ ([@evy229-B26]). pFst uses a likelihood ratio test for allele frequency differences between case--control groups while incorporating genotype likelihood information to account for potential sequencing error. SNPs and indels in candidate genomic regions were characterized using variant effect predictor (VEP; [@evy229-B61]) and the reference genome (downloaded from Ensembl January 2016; [@evy229-B68]). Each variant was classified as intergenic, intronic, synonymous, nonsynonymous, being in an untranslated region (UTR), or upstream or downstream of a particular gene (i.e., ≤5 kb of the coding sequence). We used GeneCards ([www.genecards.org](http://www.genecards.org); [@evy229-B87]) to identify putative gene functions.

Identifying Structural Variation
--------------------------------

We used Manta ([@evy229-B7]) to identify SVs in the ten individual genomes. Manta uses paired and split-read evidence to identify large indels, inversions, duplications, and translocations. We ran a joint diploid sample analysis across all individuals and identified 79,453 variants that passed default Manta filters. We then calculated Weir and Cockerham's *F*~ST~ (*θ*; [@evy229-B94]) to compare differentiation between cases and controls for each variant. Because the reference genome has only been assembled into ∼36,000 scaffolds ([@evy229-B68]) and contains many missing base pairs, more than half of the identified large indels mapped to these regions and were, therefore, false positives. We manually removed variants that mapped to regions of the reference genome with ≥50% N's. We then took the remaining top 0.1% of SVs (segmentFst did not identify any differentiated genomic regions in this data set; data not shown) and required a minimum phred-scaled quality score of 999. This conservative approach identified 35 top SVs that passed all filters.

Detecting Polygenic Selection
-----------------------------

Because conventional methods such as integrated haplotype score and derived intra-allelic nucleotide diversity have little power to detect signatures of polygenic adaptation (i.e., small allele frequency changes at many loci; [@evy229-B20]), we used Weir and Cockerham's *F*~ST~ (*θ*; [@evy229-B94]) to compare differentiation between cases and controls for six pathways ([@evy229-B76]) relevant to cancer risk and DFT1 response. We used one-sided Mann--Whitney *U* tests to compare the level of case--control differentiation in a given biological pathway to that of the rest of the genome as previously described ([@evy229-B35]). Pathways exhibiting greater differentiation than the genomic background may be evolving under positive selection. We examined six biological pathways previously shown to be associated with DFTD response and/or cancer-related traits: Cell adhesion ([@evy229-B19]; [@evy229-B53]; *n *=* *2442 genes), apoptosis (*n *=* *115; [@evy229-B19]), cancer (*n *=* *229; [@evy229-B80]), graft-versus-host (*n *=* *13; [@evy229-B80]), chemokine signaling (*n *=* *79; [@evy229-B21]), and vascular endothelial growth factor signaling (*n *=* *40; [@evy229-B96]). Genes for each pathway were identified in the Kyoto Encyclopedia of Genes and Genomes (KEGG; [@evy229-B38]). All variants within 5 kb of the coding-region of a gene were listed as a pathway variant. SNPs and indels were analyzed independently. All genes and pathways are provided in [supplementary table S1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online.

Identifying Regulatory Regions from Whole-Genome Sequences
----------------------------------------------------------

To determine if candidate variants occurred in putative regulatory regions, we used gVISTA ([@evy229-B12]) and RankVISTA to identify conserved noncoding sequences (CNS) across devils and humans. RankVISTA uses the Gumby algorithm to estimate neutral evolutionary rates from nonexonic regions in the alignment and identify statistically significant segments that evolve more slowly than the background; phylogenetically weighted log-odds conservation scores of conserved segments are translated to *P*-values using Karlin-Altschul statistics ([@evy229-B55]). The human genome (NCBI v36.1, hg18, March 2006) was used as the reference for all analyses. Identified CNS represent putative regulatory elements. We used a RankVISTA threshold of 0.5, a calculation window of 100 bp, and limited these comparisons to the candidate genomic regions identified in our segmentFst analyses described above. Candidate genomic regions that occurred on scaffolds that did not contain annotated coding sequences were excluded. For the shared SNP/indel candidate regions, we took the earliest starting and latest stopping positions to analyze the largest possible region. Because gVISTA cannot analyze sequences \>300 kb, we cut the larger genomic regions into 300 kb blocks for these analyses. Significantly conserved intronic and intergenic sequences were identified as putative regulatory elements. Results were visualized in VISTA ([@evy229-B18]; [@evy229-B57]; [@evy229-B23]) using six nondevil mammal genomes: Humans, mouse, rat, dog, horse, and rhesus monkey. SNPs and indels were then mapped to the identified CNS and annotated as putative regulatory variants.

Results
=======

Candidate Genomic Regions Underlying Tumor Regression in Tasmanian Devils
-------------------------------------------------------------------------

We identified 11 highly differentiated genomic regions between cases and controls using the SNP data ([fig. 2*A*](#evy229-F2){ref-type="fig"}). These candidate regions occurred on ten scaffolds across 5 chromosomes and contained 22 annotated genes, 10 of which had a putative immune and/or cancer-related function ([table 1](#evy229-T1){ref-type="table"}). Chromosome 6 and the X chromosome did not possess any candidate regions. Table 1Candidate Genomic Regions Identified in the SNP-Based segmentFst Analysis with Corresponding Genes and Candidate SNPsChromsomeScaffoldStart--EndGenePutative FunctionCandidate SNPs1GL83490059090--264617Protein phosphatase 2, regulatory subunit B, delta (*PPP2R2D*)[^a^](#tblfn1){ref-type="table-fn"}Cell growth/division control; Activated TLR4 signaling[^a^](#tblfn1){ref-type="table-fn"}--BCL2/adenovirus E1B 19 kDa interacting protein 3 (*BNIP3*)[^a^](#tblfn1){ref-type="table-fn"}Apoptosis and authophagy[^a^](#tblfn1){ref-type="table-fn"}--Janus kinase and microtubule interacting protein 3 (*JAKMIP3*)Microtubule and kinase binding13 intronic2GL841602886632--992998Xylulokinase (*XYLB*)Metabolism8 intronic1 downstream2GL841626476121--923043Sodium channel, voltage-gated, type XI, alpha subunit (*SCN11A*)Action potential and pain signaling4 upstreamWD repeat domain 48 (*WDR48*)[^a^](#tblfn1){ref-type="table-fn"}Deubiquitinating complex regulator; Potential tumor suppressor[^a^](#tblfn1){ref-type="table-fn"}2 intronicGolgi reassembly stacking protein 1 (*GORASP1*)Protein sorting and modification1 upstreamTetratricopeptide repeat domain 21A (*TTC21A*)Protein localization--Xin actin-binding repeat containing 1 (*XIRP1*)[^a^](#tblfn1){ref-type="table-fn"}Cellular junction function; leukemia candidate gene[^a^](#tblfn1){ref-type="table-fn"}--Solute carrier family 22, member 14 (*SLC22A14*)Molecule transport--Solute carrier family 22, member 13 (*SLC22A13*)Molecular transport and metabolism--Oxidative stress responsive 1 (*OXSR1*)[^a^](#tblfn1){ref-type="table-fn"}Kinase response to environmental stress[^a^](#tblfn1){ref-type="table-fn"}--3GL8499053117969--3162680Mediator complex subunit 12-like (*MED12L*)Transcriptional coactivation--4GL8569681213224--1266653------5GL8616228458--1345777Lymphoid-restricted membrane protein (*LRMP*)[^a^](#tblfn1){ref-type="table-fn"}Peptide delivery to MHC class I; related to b-cell lymphomas[^a^](#tblfn1){ref-type="table-fn"}--Cancer susceptibility candidate 1 (*CASC1*)[^a^](#tblfn1){ref-type="table-fn"}Microtubule and tubulin binding; related to respiratory neoplasms[^a^](#tblfn1){ref-type="table-fn"}--LYR motif containing 5 (*LYRM5*)Protein synthesis--Kirsten rat sarcoma viral oncogene homolog (*KRAS*)[^a^](#tblfn1){ref-type="table-fn"}Member of small GTPase superfamily; implicated in multiple carcinomas[^a^](#tblfn1){ref-type="table-fn"}1 intronicLamin tail domain containing 1 (*LMNTD1*)[^a^](#tblfn1){ref-type="table-fn"}Structural activity; related to respiratory neoplasms[^a^](#tblfn1){ref-type="table-fn"}30 intronic\
4 upstream\
4 downstreamRas association domain family member 8 (*RASSF8*)[^a^](#tblfn1){ref-type="table-fn"}Tumor suppressor protein; epithelial cell migration[^a^](#tblfn1){ref-type="table-fn"}--Sarcospan (*SSPN*)Structural support--5GL8616821183188--1317129Glutamate decarboxylase 2 (*GAD2*)L-glutamic acid catalysis87 intronic\
2 upstream\
1 synonymous5GL8616821500464--1544340Myosin IIIA (*MYO3A*)[^a^](#tblfn1){ref-type="table-fn"}Hearing; associated with bladder/colon cancer[^a^](#tblfn1){ref-type="table-fn"}7 intronic\
1 upstream5GL861847655--43394------5GL8621787209--28728ENSSHAG00000000783Unannotated coding sequence9 intronic\
2 downstream5GL862286963--11539------[^2]

![---Manhattan plots showing differentiation between cases and controls for (*A*) SNPs, (*B*) indels, and (*C*) structural variants. Blue points in (*A*) and (*B*) indicate scaffolds that were identified as highly differentiated candidate genomic regions by segmentFst. The three candidate indel scaffolds in (*B*) are the same scaffolds as in (*A*). Because the *x* axis is variant index rather than true genomic position (i.e., the 36,000 scaffolds of the reference genome makes robust physical mapping problematic), the scaffolds only appear slightly shifted. (*C*) Blue points indicate empirical outliers that passed all filters (see Materials and Methods). Green points indicate empirical outliers that did not pass all filters. The *y* axis in all panels represents the negative log of the pFst statistic.](evy229f2){#evy229-F2}

We identified three highly differentiated genomic regions between cases and controls using the indel data ([fig. 2*B*](#evy229-F2){ref-type="fig"}). These candidate regions occurred on three scaffolds across chromosomes 3 and 5. All three candidate regions occurred on scaffolds also identified in the SNP-based analysis. The SNP candidate genomic region on chromosome 3 was completely encompassed by the larger indel candidate region. The candidate indel region on chromosome 5 scaffold GL861622 was completely encompassed by the larger SNP candidate region, and the indel region on chromosome 5 scaffold GL861682 overlapped both candidate SNP regions identified on this scaffold ([fig. 2*A* and *B*;](#evy229-F2){ref-type="fig"}[tables 1](#evy229-T1){ref-type="table"} and [2](#evy229-T2){ref-type="table"}). The 3 candidate indel regions contained 12 annotated genes, 7 of which had a putative immune and/or cancer-related function ([table 2](#evy229-T2){ref-type="table"}). All seven genes in the candidate indel regions on chromosome 5 were identified in the SNP-based analysis, but four of the five genes identified in the candidate indel region on chromosome 3 were not identified in the SNP-based analysis (only *MED12L* was shared across the SNP and indel candidate regions on chromosome 3; [tables 1](#evy229-T1){ref-type="table"} and [2](#evy229-T2){ref-type="table"}). Three of the four genes identified only in the candidate indel region on chromosome 3 had a putative immune and/or cancer-related function ([table 2](#evy229-T2){ref-type="table"}). Table 2Candidate Genomic Regions Identified in the Indel-Based segmentFst Analysis with Corresponding Genes and Candidate IndelsChromsomeScaffoldStart--EndGenePutative FunctionCandidate Indels3GL8499052931754--3563755*MED12L*Transcriptional coactivation6 intronic1 upstream4 intronic[^b^](#tblfn3){ref-type="table-fn"}G protein-coupled receptor 87 (*GPR87*)[^a^](#tblfn2){ref-type="table-fn"}Regulated by *p53*; overexpressed in carcinomas[^a^](#tblfn2){ref-type="table-fn"}1 intronic[^b^](#tblfn3){ref-type="table-fn"}3 downstream[^b^](#tblfn3){ref-type="table-fn"}Purinergic receptor P2Y, G-protein coupled, 14 (*P2RY14*)[^a^](#tblfn2){ref-type="table-fn"}Receptor activity; immune and neuroimmune function[^a^](#tblfn2){ref-type="table-fn"}--G protein-coupled receptor 171 (*GPR171*)Ligand-binding receptor--Siah E3 ubiquitin protein ligase 2 (*SIAH2*)[^a^](#tblfn2){ref-type="table-fn"}Hypoxia response; involved in apoptosis and tumor suppression[^a^](#tblfn2){ref-type="table-fn"}--5GL861622159894--1238762*CASC1*[^a^](#tblfn2){ref-type="table-fn"}Microtubule and tubulin binding; related to respiratory neoplasms[^a^](#tblfn2){ref-type="table-fn"}1 intronic*LYRM5*Protein synthesis--*KRAS*[^a^](#tblfn2){ref-type="table-fn"}Small GTPase superfamily member; implicated in multiple carcinomas[^a^](#tblfn2){ref-type="table-fn"}--*LMNTD1*[^a^](#tblfn2){ref-type="table-fn"}Structural activity; related to respiratory neoplasms[^a^](#tblfn2){ref-type="table-fn"}7 intronic1 upstream1 downstream*RASSF8*[^a^](#tblfn2){ref-type="table-fn"}Tumor suppressor protein; epithelial cell migration[^a^](#tblfn2){ref-type="table-fn"}1 intronic5GL8616821186331--1550521*GAD2*L-glutamic acid catalysis11 intronic*MYO3A*[^a^](#tblfn2){ref-type="table-fn"}Hearing; associated with bladder/colon cancer[^a^](#tblfn2){ref-type="table-fn"}21 intronic1 upstream[^3][^4]

Candidate SNPs Underlying Tumor Regression in Tasmanian Devils
--------------------------------------------------------------

We identified 1148 SNPs in the 11 SNP-based candidate genomic regions described above ([supplementary table S2](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online), 585 of which we considered highly differentiated ($F_{\text{ST}} \geq 0.500$). Most of the highly differentiated SNPs were intergenic (69.7%) and intronic (26.8%; [fig. 3*A*](#evy229-F3){ref-type="fig"} and [table 1](#evy229-T1){ref-type="table"}). Nineteen (∼3.3%) were up or downstream of a coding-region, a single highly differentiated SNP was synonymous, and no nonsynonymous candidates were identified ([fig. 3*A*](#evy229-F3){ref-type="fig"} and [table 1](#evy229-T1){ref-type="table"}).

![---Pie charts depicting the relative frequencies of different mutational classes among the most differentiated (*A*) SNPs (*n *=* *585) and (*B*) indels (*n *=* *128) in the candidate genomic regions from [figure 2](#evy229-F2){ref-type="fig"}. Nonsyn, nonsynonymous; Syn, synonymous; UTR, untranslated region.](evy229f3){#evy229-F3}

Forty-nine candidate SNPs occurred in or near loci with putative cancer-related functions ([table 1](#evy229-T1){ref-type="table"}). We identified two highly differentiated SNPs in the introns of *WDR48* ($0.560 \leq F_{\text{ST}} \leq 0.577$), a putative tumor suppressor, and a top SNP in the intron of *KRAS* (*F*~ST~=0.765), a gene implicated in multiple carcinomas. We also identified 38 highly differentiated SNPs ($0.566 \leq F_{\text{ST}} \leq 0.790$) in or near *LMNTD1* and eight candidate SNPs ($0.500 \leq F_{\text{ST}} \leq 0.536$) in or near *MYO3A*. *LMNTD1* is related to respiratory neoplasms, and although *MYO3A* primarily functions in hearing, modifications in *MYO3A* were found to be associated with bladder and colon cancer (see Discussion; [@evy229-B44]; [@evy229-B9]).

Candidate Indels Underlying Tumor Regression in Tasmanian Devils
----------------------------------------------------------------

We identified 197 indels in the 3 indel-based candidate genomic regions ([supplementary table S3](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online), 132 of which were highly differentiated ($F_{\text{ST}} \geq 0.500$). Excluding the four ambiguous highly differentiated indels identified in the overlapping gene region on chromosome 3 (see below), most of the highly differentiated indels were intergenic (60.2%) and intronic (36.7%; [fig. 3*B*](#evy229-F3){ref-type="fig"} and [table 2](#evy229-T2){ref-type="table"}). Four indels (∼3.1%) were up or downstream of a coding-region. As expected, no indels were identified in the coding-regions or UTRs of genes ([fig. 3*B*](#evy229-F3){ref-type="fig"} and [table 2](#evy229-T2){ref-type="table"}).

For the candidate region on chromosome 3 ([fig. 2*B*](#evy229-F2){ref-type="fig"} and [table 2](#evy229-T2){ref-type="table"}), we identified four variants with ambiguous designations because *MED12L* (scaffold position 2786476--3136515) and *GPR87* (scaffold position 2912235--2934071) are overlapping genes. Overlapping genes have been documented in vertebrate genomes, including humans and other mammals (e.g., [@evy229-B51]). Based on the annotation of the reference *S. harrisii* genome (downloaded from Ensembl January 2016; [@evy229-B68]), *GPR87* is nested within *MED12L*. We identified one highly differentiated variant (*F*~ST~=0.644) in intronic regions of both genes as well as three variants that occurred in an intronic region of *MED12L* and downstream of *GPR87* ($0.571 \leq F_{\text{ST}} \leq 0.644$). *MED12L* functions in transcriptional coactivation, and *GPR87* is regulated by *p53* ([table 2](#evy229-T2){ref-type="table"}).

Several other candidate indels also occurred in or near loci with putative cancer-related functions ([table 2](#evy229-T2){ref-type="table"}). We identified seven intronic candidates ($0.804 \leq F_{\text{ST}} \leq 0.864$) as well as individual up- (*F*~ST~=0.884) and downstream candidates (*F*~ST~=0.831) for *LMNTD1*. We also identified candidate indels in the introns of *RASSF8* (*F*~ST~=0.686) and *CASC1* (*F*~ST~=0.556). *RASSF8* is a putative tumor suppressor, and *CASC1* has also been associated with neoplasms, similar to *LMNTD1* ([table 2](#evy229-T2){ref-type="table"}). Twenty-one intronic ($0.516 \leq F_{\text{ST}} \leq 0.703$) and an upstream candidate indel (*F*~ST~=0.703) were found for *MYO3A* ([table 2](#evy229-T2){ref-type="table"}); *MYO3A* also possessed several candidate SNPs ([table 1](#evy229-T1){ref-type="table"}) and has been implicated in cancer susceptibility ([@evy229-B44]; Chung et al. [@evy229-B9]).

Candidate SVs Underlying Tumor Regression in Tasmanian Devils
-------------------------------------------------------------

We identified 35 highly differentiated putative SVs that passed all filters ([fig. 2*C*](#evy229-F2){ref-type="fig"}). Of these 35 candidate SVs, 21 were intergenic, 11 were found in the introns of 10 genes, 1 variant was upstream of a gene, and 2 variants were downstream of a single gene. Of the 14 variants in or near genes, we identified 6 insertions (58--584 bp), 2 deletions (95--614 bp), and 6 putative translocations ([table 3](#evy229-T3){ref-type="table"}). Both deletions and all but one insertion occurred in introns; one insertion was upstream of a coding-sequence. Of the six putative translocations, four occurred in introns and two occurred in downstream regions, although both putative downstream translocations also involved introns of another gene (i.e., we genotyped six highly differentiated translocations, but two overlapped, leaving four candidate translocations; see below; [table 3](#evy229-T3){ref-type="table"}). Table 3Candidate Genes Identified in the Structural Variant AnalysisChromsomeScaffoldPositionTypeGenePutative Function2GL84146525285158 bp insertion intronDTW domain containing 2 (*DTWD2*)Mitochondrion protein targetingGL841584117658295 bp deletion intronBMP binding endothelial regulator (*BMPER*)Bone morphogenetic protein inhibition3GL849630133609584 bp insertion upstreamSolute carrier family 38 member 11 (*SLC38A11*)Amino acid transportGL849631677692278 bp insertion intronCysteine-serine-rich nuclear protein 3 (*CSRNP3*)[^a^](#tblfn4){ref-type="table-fn"}Transcriptional activator regulator; apoptosis[^a^](#tblfn4){ref-type="table-fn"}4GL8569531140408247 bp insertion intronMitogen-activated protein kinase kinase kinase 5 (*MAP3K5*)[^a^](#tblfn4){ref-type="table-fn"}Apoptosis signal transduction[^a^](#tblfn4){ref-type="table-fn"}GL856993210323Translocation of intron with intergenic region on chromosome 3 (GL849549)Tripartite motif containing 33 (*TRIM33*)[^a^](#tblfn4){ref-type="table-fn"}E3 ubiquitin-protein ligase; related to carcinomas[^a^](#tblfn4){ref-type="table-fn"}5GL8615911045356614 bp deletion intronENTH domain containing 1 (*ENTHD1*)UnknownGL861622511673Translocation of downstream region with intron of tankyrase (*TNKS*) on chromosome 6 (see below)*LMNTD1*[^a^](#tblfn4){ref-type="table-fn"}Structural activity; related to respiratory neoplasms[^a^](#tblfn4){ref-type="table-fn"}511686Translocation of downstream region with intron of *TNKS* on chromosome 6 (see below)*LMNTD1*[^a^](#tblfn4){ref-type="table-fn"}Structural activity; related to respiratory neoplasms[^a^](#tblfn4){ref-type="table-fn"}GL861672157814569 bp insertion intronGTP binding protein 4 (*GTPBP4*)Cell signaling6GL8647361234425Translocation of intron with downstream region of *LMNTD1* on chromosome 5 (see above)*TNKS*[^a^](#tblfn4){ref-type="table-fn"}Wnt signaling; target of cancer treatment[^a^](#tblfn4){ref-type="table-fn"}1234867Translocation of intron with downstream region of *LMNTD1* on chromosome 5 (see above)*TNKS*[^a^](#tblfn4){ref-type="table-fn"}Wnt signaling; target of cancer treatment[^a^](#tblfn4){ref-type="table-fn"}GL86475378910395 bp insertion intronSEC31 homolog A (*SEC31A*)[^a^](#tblfn4){ref-type="table-fn"}Vesicle budding; related to inflammatory myofibroblastic tumors[^a^](#tblfn4){ref-type="table-fn"}XGL8676073118283Translocation of intron with intergenic region on chromosome 1 (GL835007)Dachshund family transcription factor 2 (*DACH2*)Transcription factor[^5]

Six of the 12 genes associated with a candidate SV were implicated in immune-response and/or cancer-risk ([table 3](#evy229-T3){ref-type="table"}). We identified insertions in the introns of *CSRNP3*, *MAP3K5*, and *SEC31A*; the former two genes are involved with apoptosis, and the latter is associated with inflammatory myofibroblastic tumors. We also found putative translocations involving three candidate genes ([table 3](#evy229-T3){ref-type="table"}). We identified a putative translocation between the intron of *TRIM33*, which is involved with the ligation of E3 ubiquitin-protein and is related to carcinomas, with an intergenic region on chromosome three. We also identified two putative translocations between the downstream regions of *LMNTD1* and the intronic regions of *TNKS*. *LMNTD1* has been associated with respiratory neoplasms and was identified as a candidate gene in both the SNP ([table 1](#evy229-T1){ref-type="table"}) and indel ([table 2](#evy229-T2){ref-type="table"}) analyses. *TNKS* is involved with Wnt signaling and associated with various forms of human cancer ([table 3](#evy229-T3){ref-type="table"}).

Detecting the Polygenic Basis of the Regression Phenotype
---------------------------------------------------------

*F* ~ST~ distributions for all six biological pathways for SNPs ($0.19 \leq P \leq 1.00$) and indels ($0.83 \leq P \leq 1.00$) were nearly identical to that of the rest of the genome, indicating an absence of detectable polygenic selection in these particular pathways ([supplementary fig. S1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online).

Identification of Putative Regulatory Elements in the Candidate Genomic Regions
-------------------------------------------------------------------------------

We identified CNS in six of the seven candidate genomics regions analyzed; the first candidate region on chromosome 2 (scaffold GL841602) did not return a match. Although we identified between 1 and 52 CNS per candidate genomic region, only one candidate genomic region, scaffold GL861682 on chromosome 5, possessed variants in the identified CNS ([fig. 4](#evy229-F4){ref-type="fig"}).

![---VISTA plot showing conserved sequences across devils and six other mammals for a candidate genomic region containing *MYO3A*. (*A*) We plotted 1,400,000--1,500,000 on devil chromosome 5 scaffold GL861682. Two conserved intronic sequences (*B* and *C*), indicated by the red boxes in (*A*), possessed candidate SNPs that were highly differentiated ($F_{\text{ST}} \geq 0.491$) between cases and controls, suggesting that these SNPs may lead to regulatory variation in *MYO3A*. Genomic position in the reference human genome is listed on the *x* axis in all panels. Percent similarity is shown on the *y* axis where the blue line indicates 70% identity in all panels. Asterisks represent approximate location of candidate SNPs. CNS, conserved noncoding sequence; UTR, untranslated region.](evy229f4){#evy229-F4}

On chromosome 5 scaffold GL861682, we identified 23 conserved intronic sequences, all of which were introns for *MYO3A*, and a single conserved intergenic sequence; these regions were 102--541 bp and 67.5--85.4% similar at the sequence level. Two of the conserved *MYO3A* intronic sequences, which represent putative regulatory elements, possessed SNPs that were highly differentiated between cases and controls ([fig. 4](#evy229-F4){ref-type="fig"}). The first candidate regulatory intronic region (position 1438502--1438639, 73.6% similarity to the human genome) possessed a highly differentiated SNP at position 1438555 (*F*~ST~=0.536). The second candidate regulatory intronic region (position 1498234--1498453, 73.3% similarity to the human genome) possessed two candidate SNPs at positions 1498270 (*F*~ST~=0.536) and 1498411 (*F*~ST~=0.491).

Discussion
==========

We predicted that the genomic basis of tumor regression in Tasmanian devils would be 1) polygenic; 2) involve specific biological pathways related to cancer risk and DFT1 response; and 3) be biased toward putative regulatory rather than protein-coding regions. We found three highly differentiated candidate genomic regions, indicating that the genomic basis of tumor regression in Tasmanian devils was polygenic. We did not detect signatures of polygenic selection in the six pathways investigated, suggesting that the genetic basis of tumor regression is either associated with the candidate genomic regions discussed above and/or other biological pathways. We identified putative regulatory variation in genes related to immune response and/or cancer risk but no nonsynonymous variation, suggesting that natural DFT1 regression may be driven, at least in part, by differential host expression of key candidate genes. We discuss each outcome in detail below.

First, we identified three highly differentiated candidate regions across chromosomes 3 and 5. Although not all variants in these candidate regions were necessarily associated with the regression phenotype and may simply be linked to one or a few large-effect variants, the strong signal of differentiation across multiple genomic regions suggested that the regression phenotype was indeed polygenic. These regions were independently identified in the SNP- and indel-based analyses and contained candidate genes such as *GPR87*, *CASC1*, *KRAS*, *RASSF8*, and *LMNTD1*, all of which contained one or more candidate variants. *LMNTD1* was identified as a candidate gene in the SNP-, indel-, and SV-based analyses, although the SV-based results must be interpreted with caution; the fragmented state of the reference genome (i.e., ∼36,000 scaffolds) made interpretation difficult.

Second, we did not detect signatures of polygenic selection in the six pathways investigated. Given that tumor regressions were first detected in 2009 ([@evy229-B77]; [@evy229-B96]) and that first-step mutations are often of large-effect ([@evy229-B79]), minor allele frequency changes at many loci may not have had enough time to occur (e.g., ∼4--5 generations assuming a 2-year generation time; [@evy229-B59]; [@evy229-B29]). The polygenic basis of DFT1 regression may therefore be in the form of a few, large-effect variants rather than many variants of small-effect, consistent with other work investigating the genetic basis of DFT1-related phenotypes in devils (e.g., survival following infection; [@evy229-B53]).

Third, none of the candidate variants were nonsynonymous, and only a single candidate synonymous SNP was identified, suggesting that differential expression of key candidate genes in devils may play a role in tumor regression. Indeed, [@evy229-B96] did not find any candidate SNPs in coding-sequences using GWA approaches investigating the same trait, and CTVT regression in dogs also appears to be driven, at least in part, by differential gene expression ([@evy229-B21]). Noncoding variation has also repeatedly been linked to tumorigenesis and other diseases in humans (e.g., [@evy229-B56]). Bias toward differential expression rather than nonsynonymous variation, however, is not specific to tumor regression or cancer-related phenotypes. Several studies have suggested that adaptive expression differentiation may be more likely than adaptive changes to coding regions, at least for rapid adaptation in complex phenotypes, because more mutational mechanisms exist for altering expression levels than for protein-coding sequences ([@evy229-B22]; [@evy229-B42]; [@evy229-B54]). Our results are consistent with these expectations.

We also found three candidate SNPs in two significantly conserved intronic sequences in *MYO3A*. Introns can function as regulatory elements (e.g., [@evy229-B50]; [@evy229-B93]), and the conservation of these intronic regions across ∼160 Myr of evolution (marsupial-placental split; [@evy229-B48]) indicated that these sequences may have an important regulatory function. These three candidate SNPs, therefore, may lead to differential expression of *MYO3A* between cases and controls. Although *MYO3A* primarily functions in transferase/kinase activity and plays a key role in hearing in humans, *MYO3A* is highly methylated in bladder tumors ([@evy229-B9]). A GWA study also found that an SNP in the intron of *MYO3A* was associated with an increased risk for colon cancer in humans ([@evy229-B44]), similar to our results (although the candidate colon cancer SNP, rs11014993, occurred in a different intron). Future transcriptomic and functional genomic studies of serially sampled devils with and without the regression phenotype are needed to determine if *MYO3A*, along with the other candidate genes, are differentially expressed to determine what role these genes may have in tumor regression.

Despite substantial statistical limitations due to the rarity of the regression phenotype and therefore unavoidable small sample sizes, [@evy229-B96] used a GWA framework and found evidence that SNPs in the introns of loci involved with angiogenesis, particularly *PAX3*, may be associated with tumor regression. *PAX3* occurs on chromosome 3 but on a different scaffold than the candidate region we identified on the same chromosome. We did identify variants in the introns as well as up and downstream of *PAX3*, but none of these variants were highly differentiated. The top variant for *PAX3* was an intronic SNP (*F*~ST~=0.307), but mean *F*~ST~ for *PAX3* intronic SNPs was ∼0.026 and all *F*~ST~ estimates for indels near *PAX3* were ∼0. *PAX3*, however, is involved in angiogenesis through regulation of bone morphogenic proteins (BMP). We found a 95-bp deletion in the intron of *BMPER* on chromosome 2, indicating that angiogenesis may indeed play an important role in natural tumor regression (although our polygenic selection analysis suggested otherwise).

Comparative oncology should lead to advances in both human and animal health ([@evy229-B82]), and tumor regression is not specific to transmissible cancers. Spontaneous tumor regression, albeit rare (∼1 in 60--100,000 cases; [@evy229-B65]), has been documented in human cancers ([@evy229-B83]). One such cancer is Merkel cell carcinoma (MCC), a rare type of skin cancer that often appears on the face, head, or neck in the form of a nodule ([@evy229-B27]). MCC is of neuroendocrine origin ([@evy229-B27]) and may be associated with Merkel cell polyomavirus, somewhat similar to DFT1's neuroectoderm/Schwann cell origin and transmissible nature ([@evy229-B69]). The first spontaneous regression of MCC was documented in 1986 ([@evy229-B71]), and regression has occurred at least 22 times since. The mechanism of MCC regression is unclear but may be driven by a T-cell-mediated immune response ([@evy229-B10]; [@evy229-B73]).

Understanding the genetic basis of regression in DFT1 and other nonhuman cancers may enable the identification of general mechanisms underlying tumor regression in MCC and other human cancers. Indeed, ethical considerations often preclude investigating natural, untreated tumor progression in human cancers, highlighting the importance of comparative oncological studies investigating the genetic basis of general tumor phenotypes such as regression. The nonlinear relationship between genotype and cancer-related traits has been labeled as one of the biggest challenges in biomedical sciences ([@evy229-B40]), and comparative oncology should advance our knowledge of cancer progression, tumor regression, and cancer-normal cell interactions and coevolution ([@evy229-B82]). We identified specific, putative regulatory variants in or near genes related to immune response and/or cancer risk that differentiated cases from controls, indicating that natural tumor regression may be driven, at least in part, by differential host expression of key genes. Our results support the concept that host immune response is necessary for triggering tumor regression ([@evy229-B21]), providing candidate genes and mechanisms that may translate to novel treatments in human and nonhuman cancers.

Supplementary Material
======================
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Click here for additional data file.
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[^1]: **Data deposition:** All raw data were deposited in the Sequence Read Archive (SRA) under BioProject PRJNA450403 and accessions SRR7015138, SRR7015139, SRR7015141--SRR7015147, and SRR7015149.

[^2]: Putative immune or cancer-related function. Candidate SNPs were variants with $F_{\text{ST}} \geq 0.5$.

[^3]: Putative immune or cancer-related function.

[^4]: Indels found in overlapping open-reading frames and, therefore, with ambiguous designations. Candidate indels were variants with $F_{\text{ST}} \geq 0.5$. Abbreviated gene names were defined in [table 1](#evy229-T1){ref-type="table"}.

[^5]: Putative immune or cancer-related function. Abbreviated gene names were defined in [tables 1](#evy229-T1){ref-type="table"} and [2](#evy229-T2){ref-type="table"}.
